Jan 11, 2024 / 12:30AM GMT
Ethan Taylor JPMorgan-Analyst
Good afternoon, everyone, and welcome to the Verona Pharma company presentation. My name is Ethan Taylor. I'm an associate in JPMorgan's healthcare investment banking group. It is my pleasure to introduce David Zaccardelli, President and CEO of Verona Pharma.
A quick note, there will be some time at the end of the presentation for audience Q&A, so please have some questions ready. And with that, David, please take it away.
David Zaccardelli - Verona Pharma PLC - President, Chief Executive Officer, Executive Director
Great. Thank you so much, and good afternoon, everyone. It's a pleasure to be here to give you an update on Verona Pharma and our lead compound, ensifentrine. With that, I just want to remind you we'll be making forward-looking statements and refer you to our SEC filings for all risk factors.
So ensifentrine has been developed for the maintenance treatment of COPD. It is under FDA review, and we'll talk more about that today. There are a few things I'd like to remind you as we talk about
Verona Pharma PLC at JPMorgan Healthcare Conference Transcript
Jan 11, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers